0.7295
4.01%
-0.0305
Pre-market:
.7307
0.0012
+0.16%
Seres Therapeutics Inc stock is currently priced at $0.7295, with a 24-hour trading volume of 5.81M.
It has seen a -4.01% decreased in the last 24 hours and a -5.11% declined in the past month.
The chart indicates a potential bearish trend, as the stock is below the $0.7306 pivot point. If it approaches the $0.6582 support level, significant changes may occur.
Previous Close:
$0.76
Open:
$0.75
24h Volume:
5.81M
Market Cap:
$110.16M
Revenue:
$126.33M
Net Income/Loss:
$-113.72M
P/E Ratio:
-0.5883
EPS:
-1.24
Net Cash Flow:
$-125.33M
1W Performance:
+16.29%
1M Performance:
-5.11%
6M Performance:
-52.48%
1Y Performance:
-88.78%
Seres Therapeutics Inc Stock (MCRB) Company Profile
Name
Seres Therapeutics Inc
Sector
Industry
Phone
617-945-9626
Address
200 Sidney Street, 4th Floor, Cambridge, MA
Seres Therapeutics Inc Stock (MCRB) Upgrades & Downgrades
Date | Action | Analyst | Rating Change |
---|---|---|---|
Jun-26-23 | Resumed | Oppenheimer | Outperform |
Apr-21-23 | Initiated | JP Morgan | Neutral |
Jul-23-21 | Downgrade | Goldman | Neutral → Sell |
May-18-21 | Resumed | Goldman | Neutral |
Mar-05-21 | Upgrade | Chardan Capital Markets | Neutral → Buy |
Sep-18-20 | Downgrade | Chardan Capital Markets | Buy → Neutral |
Aug-18-20 | Initiated | Piper Sandler | Overweight |
Aug-11-20 | Reiterated | H.C. Wainwright | Buy |
Aug-11-20 | Upgrade | Jefferies | Hold → Buy |
Apr-30-19 | Initiated | Jefferies | Hold |
Oct-22-18 | Initiated | Chardan Capital Markets | Buy |
Oct-13-17 | Initiated | Oppenheimer | Outperform |
Aug-04-17 | Reiterated | H.C. Wainwright | Buy |
Feb-01-17 | Reiterated | FBR & Co. | Outperform |
Aug-12-16 | Reiterated | FBR Capital | Outperform |
Aug-01-16 | Downgrade | BofA/Merrill | Buy → Neutral |
Aug-01-16 | Reiterated | H.C. Wainwright | Buy |
Jul-29-16 | Resumed | H.C. Wainwright | Buy |
Mar-30-16 | Initiated | FBR Capital | Outperform |
Mar-03-16 | Initiated | Guggenheim | Buy |
Jan-25-16 | Initiated | H.C. Wainwright | Buy |
Oct-22-15 | Upgrade | BofA/Merrill | Neutral → Buy |
Jul-22-15 | Initiated | Canaccord Genuity | Buy |
Jul-21-15 | Initiated | Goldman | Neutral |
Jul-21-15 | Initiated | Leerink Partners | Outperform |
View All
Seres Therapeutics Inc Stock (MCRB) Latest News
Emerson Electric To Rally More Than 19%? Here Are 10 Top Analyst Forecasts For Wednesday
Benzinga
Halozyme Therapeutics (HALO) Surges 5.6%: Is This an Indication of Further Gains?
Zacks Investment Research
Dow Tumbles Over 200 Points; US Trade Gap Narrows In November
Benzinga
Seres Therapeutics: Evaluating Vowst's Market Challenges (Rating Downgrade)
Seeking Alpha
Why Fortinet Shares Are Trading Lower By Around 17%? Here Are Other Stocks Moving In Friday's Mid-Day Session
Benzinga
Nasdaq Gains 1%; US Adds 150,000 Jobs In October
Benzinga
Seres Therapeutics Inc Stock (MCRB) Financials Data
Seres Therapeutics Inc (MCRB) Revenue 2024
MCRB reported a revenue (TTM) of $126.33 million for the quarter ending December 31, 2023, a +1,672% rise year-over-year.
Seres Therapeutics Inc (MCRB) Net Income 2024
MCRB net income (TTM) was -$113.72 million for the quarter ending December 31, 2023, a +54.54% increase year-over-year.
Seres Therapeutics Inc (MCRB) Cash Flow 2024
MCRB recorded a free cash flow (TTM) of -$125.33 million for the quarter ending December 31, 2023, a +47.48% increase year-over-year.
Seres Therapeutics Inc (MCRB) Earnings per Share 2024
MCRB earnings per share (TTM) was -$0.90 for the quarter ending December 31, 2023, a +61.54% growth year-over-year.
About Seres Therapeutics Inc
Seres Therapeutics, Inc., a microbiome therapeutics platform company, engages in developing biological drugs designed to restore health by repairing the function of a dysbiotic microbiome. Its lead product candidate is SER-109, a bacterial spore ecology, which is in Phase III clinical study to treat multiply recurrent Clostridium difficile infection (CDI). The company is also developing SER-287 that is in Phase Ib clinical study in patients with mild-to-moderate ulcerative colitis; and SER-262, a multi-strain Ecobiotic microbiome therapeutic candidate, which is in Phase Ib study in patients with primary CDI. In addition, its product candidates in pre-clinical development comprise SER-301, an Ecobiotic microbiome therapeutic candidate for the treatment of inflammatory bowel disease; SER-401 for use with checkpoint inhibitors in patients with solid tumors; and SER-155, an Ecobiotic microbiome therapeutic candidate for the prevention of transplant-related mortality. Seres Therapeutics, Inc. has a strategic collaboration with Nestle Health Science and Memorial Sloan Kettering Cancer Center. The company was formerly known as Seres Health, Inc. and changed its name to Seres Therapeutics, Inc. in May 2015. Seres Therapeutics, Inc. was founded in 2010 and is headquartered in Cambridge, Massachusetts.
Cap:
|
Volume (24h):